Brief: Lipocine LPCN 1154 Meets Bioequivalence With IV Brexanolone In Pivotal Study
25/06/2024 14:09
June 25 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC: LPCN 1154 MEETS BIOEQUIVALENCE WITH IV
BREXANOLONE
IN PIVOTAL STUDY
* LIPOCINE INC: ON TRACK FOR NDA FILING, TARGETED BY END OF
Q4
* LIPOCINE INC: LPCN 1154 WAS WELL TOLERATED WITH NO
SEDATION OR
SOMNOLENCE EVENTS OBSERVED
Source text for Eikon: ID:nPn15RylRa
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy